German biotech Medigene AG is focused on developing T-cell receptor engineered T-cell (TCR-T) therapies for the treatment of solid tumors. After $29.4m was raised in 2022, a further $6.3m this year has provided a small cash boost to fund R&D plans.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?